Clinical Trials

🔬 Top Active Longevity Clinical Trials

Live data from ClinicalTrials.gov — Stars indicate evidence strength (phase + enrollment size)

Trial Phase Enrolled Est. End Evidence Intervention
CALM-AF-AI: Counteracting Age-related Loss of Muscle Wi Phase 1 12 2028-06-30 ★★☆☆☆ AAV9-Follistatin gene therapy, VEGF Plasmid
Rapalog Pharmacology (RAP PAC) Study Phase 1 72 2028-12 ★★★☆☆ Sirolimus, Everolimus
MTOR Inhibitors in Older Adults Phase 1 60 2027-11-13 ★★★☆☆ Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg O
A Pilot Study on Reverse Aging (The REVERSE Study) EARLY/Phase 1 52 2026-05 ★★☆☆☆ Rapamycin (Tablets), Prolon diet
Effect of Rapamycin in Ovarian Aging Phase 2 50 2026-09 ★★★★☆ Rapamycin, Placebo
Role of Metformin on Muscle Health of Older Adults EARLY/Phase 1 64 2026-11-01 ★★☆☆☆ Metformin (Bed Rest), Placebo (Bed Rest)
Metformin as an add-on or Monotherapy in Treatment of A Phase 2 30 2027-06-01 ★★★☆☆ metformin, Placebo
Pilot Study on Evaluating the Geroprotective Effect of Phase 2 130 2028-07-31 ★★★★☆ Metformin Hydrochloride tablet, Placebo
Senolytics to Improve Osteoporosis Therapy Phase 2 120 2026-04-30 ★★★★☆ Dasatinib 100 Mg Oral Tablet, Quercetin 1.250
ALSENLITE: Senolytics for Alzheimer’s Disease Phase 1 20 2026-06 ★★☆☆☆ Dasatinib, Quercetin

★★★★★ = Phase 3 + large enrollment | ★★★ = Phase 2 | ★★ = Early phase | Source: ClinicalTrials.gov


Active Longevity & Healthspan Clinical Trials

Live data from ClinicalTrials.gov. These are currently recruiting or active studies related to longevity & healthspan.

Phase 1
Phase 2
Phase 3 / Recruiting
Active, not recruiting
Last updated: March 14, 2026 · 30 active trials
Phase 1, Phase 2
Recruiting
Enrollment: 12
Est. completion: 2028-06-30
AAV9-Follistatin gene therapy, VEGF Plasmid
N/A
Recruiting
Enrollment: 20
Est. completion: 2026-06-30
Sleep and dietary counseling, Supervised exercise and exergaming program, Motivational interviewing
N/A
Recruiting
Enrollment: 40
Est. completion: 2027-01-01
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Phase 1
Recruiting
Enrollment: 72
Est. completion: 2028-12
Sirolimus, Everolimus
Phase 4
Active Not Recruiting
Enrollment: 40
Est. completion: 2027-09-18
Tirzepatide, Placebo
Phase 1, Phase 2
Recruiting
Enrollment: 60
Est. completion: 2027-11-13
Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet
EARLY_Phase 1
Active Not Recruiting
Enrollment: 52
Est. completion: 2026-05
Rapamycin (Tablets), Prolon diet
N/A
Recruiting
Enrollment: 80
Est. completion: 2026-12-30
Fisetin intervention, Placebo, Urolithin A intervention
Phase 2
Active Not Recruiting
Enrollment: 50
Est. completion: 2026-09
Rapamycin, Placebo
N/A
Recruiting
Enrollment: 66
Est. completion: 2027-06-02
Semaglutide, Tirzepatide, Metformin
Phase 2
Active Not Recruiting
Enrollment: 106
Est. completion: 2026-09
Everolimus 0.5 MG once per day, Everolimus 5 MG once per week, Placebo once per day
EARLY_Phase 1
Active Not Recruiting
Enrollment: 64
Est. completion: 2026-11-01
Metformin (Bed Rest), Placebo (Bed Rest), Metformin (2 week run-in only)
Phase 4
Recruiting
Enrollment: 220
Est. completion: 2026-07-31
Semaglutide, Empagliflozin, Minigastric bypass, Analimentary detoxication
Phase 2
Recruiting
Enrollment: 30
Est. completion: 2027-06-01
metformin, Placebo
Phase 2
Enrolling By Invitation
Enrollment: 40
Est. completion: 2027-04
Fisetin, Placebo oral capsule
N/A
Recruiting
Enrollment: 120
Est. completion: 2035-09-20
Fisetin, Placebo
Phase 1, Phase 2
Active Not Recruiting
Enrollment: 70
Est. completion: 2027-03-31
Fisetin, Placebo
N/A
Enrolling By Invitation
Enrollment: 10
Est. completion: 2031-09
Spermidine
Phase 1
Recruiting
Enrollment: 22
Est. completion: 2026-07-01
lamivudine, rapamycin, Exercise Regimen
EARLY_Phase 1
Recruiting
Enrollment: 194
Est. completion: 2028-07
Rapamycin, Everolimus, Placebo
EARLY_Phase 1
Enrolling By Invitation
Enrollment: 150
Est. completion: 2025-12-01
GLP-1, Placebo
Phase 2, Phase 3
Recruiting
Enrollment: 150
Est. completion: 2025-08
Metformin, Rapamycin, Naltrexone
N/A
Recruiting
Enrollment: 30
Est. completion: 2027-06-30
Nicotinamide Riboside, Placebo
N/A
Recruiting
Enrollment: 28
Est. completion: 2026-03
Nicotinamide Riboside (NR), Placebo
Phase 4
Enrolling By Invitation
Enrollment: 30
Est. completion: 2027-03-31
semaglutide or tirzepatide, Lifestyle modification intervention
Phase 2
Recruiting
Enrollment: 85
Est. completion: 2025-12
TRIIM Treatment, Active Control
N/A
Recruiting
Enrollment: 70
Est. completion: 2025-06-30
Niagen®, NAD+, Placebo
Phase 2
Recruiting
Enrollment: 130
Est. completion: 2028-07-31
Metformin Hydrochloride tablet, Placebo
Phase 2
Recruiting
Enrollment: 118
Est. completion: 2025-06-01
Nicotinamide riboside, Placebo

Data sourced from ClinicalTrials.gov. This page is for informational purposes only. Always consult your healthcare provider.